内镜鼻窦手术与生物制剂治疗慢性鼻窦炎伴鼻息肉的比较分析
本研究将2011至2019年间接受内镜鼻窦手术(ESS)的111例慢性鼻窦炎伴鼻息肉(CRSwNP)患者的前瞻性多中心队列数据,与三期生物制剂试验数据进行比较。结果显示,在24周时ESS的SNOT-22改善优于一项dupilumab试验和两项omalizumab试验,鼻息肉评分显著低于dupilumab和omalizumab;52周时ESS的SNOT-22改善与dupilumab相似,但鼻息肉评分仍显著低于dupilumab和mepolizumab。
要点
- 24周时ESS的SNOT-22改善优于一项dupilumab试验和两项omalizumab试验。
- 24周和52周时ESS的鼻息肉评分均显著低于dupilumab组。
- 52周时ESS的SNOT-22改善与dupilumab相似,但鼻息肉评分更低。
核心结论
- 24周和52周时,ESS与dupilumab相比提供相似的SNOT-22改善。
- 24周时ESS和dupilumab提供相似的嗅觉识别改善。
- 与omalizumab相比,ESS提供更优的SNOT-22改善。
- 与omalizumab、dupilumab和mepolizumab相比,ESS提供显著更大的鼻息肉体积缩小。
研究设计与样本
- 前瞻性多中心队列研究,纳入2011至2019年间接受ESS的CRSwNP患者,与三期生物制剂试验数据比较。
- 共111例CRSwNP患者符合改良纳入标准(改良自Dupilumab-LIBERTY-NP-24&52、omalizumab-POLYP-1&2和Mepolizumab-SYNAPSE临床试验)。
- 在24周和52周时(可行时)比较基线特征和结局指标。
主要发现
- ESS组与生物制剂组在基线年龄、性别、哮喘状态、阿司匹林加重呼吸道疾病状态、嗅觉识别、LK息肉评分和Lund-Mackay CT评分上无统计学显著差异。
- 24周时,ESS在SNOT-22改善上显著优于一项(两项中的一项)dupilumab试验(p < 0.05)和两项omalizumab试验(p < 0.001)。
- 24周时,ESS组鼻息肉评分(NPS)显著低于dupilumab组(p < 0.001)和omalizumab组(p < 0.001),尽管嗅觉识别改善相当(p > 0.05)。
- 52周时,ESS组SNOT-22改善与dupilumab组统计学相似(p = 0.21),但NPS在ESS组仍显著低于dupilumab组(p < 0.001)和mepolizumab组(p < 0.001)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Comparative effectiveness research between endoscopic sinus surgery (ESS) and biologic therapy for severe chronic rhinosinusitis with nasal polyposis (CRSwNP) is a nascent field as new therapeutic modalities become clinically available. METHODS: A prospective, multicenter cohort of CRSwNP patients, undergoing ESS between 2011 and 2019, were compared to phase-3 biologic trial data. Patients undergoing ESS received baseline nasal endoscopy quantified via Lund-Kennedy (LK) grading. Patients meeting inclusion criteria, modified from Dupilumab-LIBERTY-NP-24&52, omalizumab-POLYP-1&2, and Mepolizumab-SYNAPSE clinical trials, were included in this study. Baseline characteristics and outcome measures were compared between these cohorts at 24 weeks and 52 weeks, when possible. RESULTS: A total of 111 CRSwNP patients met modified inclusion criteria. There were no statistically significant differences in baseline age, sex, asthma status, aspirin-exacerbated respiratory disease status, smell identification, LK-polyp score, and Lund-Mackay computed tomography (CT) scores between ESS and biologic groups. At 24 weeks, ESS demonstrated significantly greater improvements in 22-item Sino-Nasal Outcome Test (SNOT-22) compared to one (of two) dupilumab trials (p < 0.05) and both omalizumab trials (p < 0.001). ESS associated with significantly lower nasal polyp scores (NPS) compared to dupilumab (p < 0.001) and omalizumab (p < 0.001), despite comparable improvements in smell identification (p > 0.05). At 52 weeks, ESS resulted in statistically similar improvement in SNOT-22 scores compared to dupilumab (p = 0.21), but NPS remained significantly lower in the ESS group compared to dupilumab (p < 0.001) and mepolizumab (p < 0.001). CONCLUSION: At 24 weeks and 52 weeks, ESS offers comparable SNOT-22 improvements compared to dupilumab. ESS and dupilumab offer comparable improvement in smell identification at 24 weeks. Compared to omalizumab, ESS offers superior SNOT-22 improvements. ESS offers significantly greater reductions in polyp size compared to omalizumab, dupilumab, and mepolizumab therapies.
引用
- Miglani A, Soler ZM, Smith TL, et al. A comparative analysis of endoscopic sinus surgery versus biologics for treatment of chronic rhinosinusitis with nasal polyposis. Int Forum Allergy Rhinol. 2022. PMID: 35980852. doi:10.1002/alr.23059
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。